8-K: HeartBeam Appoints CEO Robert Eno to Board of Directors

HeartBeam, Inc. appoints CEO Robert Eno to its Board of Directors to support U.S. commercialization and growth.

Summary

• HeartBeam, Inc. announced the appointment of Chief Executive Officer Robert Eno to its Board of Directors, effective May 5, 2025.
• The Board expanded from eight to nine members to accommodate this addition.
• Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024.
• HeartBeam received FDA clearance for its patented 3D ECG technology in December 2024 and submitted an FDA application for the 12-lead ECG Synthesis Software in January 2025.
• The Company plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG Synthesis Software.
• Earlier this year, the Company initiated an Early Access Program to obtain important feedback on the end-to-end clinical workflow, ensure operational readiness and establish an early adopter funnel.

Sentiment

Score: 7

Explanation: The announcement is positive, highlighting the appointment of the CEO to the board and progress towards commercialization. However, the company's success is contingent on future FDA clearances, introducing some uncertainty.

Positives

• The appointment of the CEO to the Board of Directors strengthens strategic oversight.
• The expansion of the Board reflects the company's commitment to leadership and innovation.
• FDA clearance for the 3D ECG technology was received in December 2024.
• The Early Access Program will help refine the clinical workflow and ensure operational readiness.

Risks

• The company's future performance depends on receiving FDA clearance for the 12-lead ECG Synthesis Software.
• Commercialization is contingent upon receiving FDA clearance for the 12-lead ECG Synthesis Software.
• The document contains forward-looking statements that involve risks and uncertainties as detailed in the company's SEC filings.

Future Outlook

HeartBeam plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG Synthesis Software and is focused on transforming cardiac care through its innovative technology.

Management Comments

• Rich Ferrari, Executive Chairman, stated that Rob's expertise complements the Board's skillset and strengthens strategic oversight.
• Robert Eno stated he is honored to join the HeartBeam Board and looks forward to driving the company's commercial success.

Industry Context

HeartBeam is positioning itself as a leader in remote cardiac monitoring with its 3D ECG technology, aiming to provide personalized insights and redefine cardiac health management outside of traditional medical facilities.

Comparison to Industry Standards

• HeartBeam's 3D ECG technology aims to improve upon traditional 12-lead ECG systems by offering a cable-free, portable solution.
• Companies like AliveCor and BioTelemetry also operate in the remote cardiac monitoring space, but HeartBeam differentiates itself with its unique 3D ECG approach.
• The company's focus on synthesizing a 12-lead ECG from 3 non-coplanar directions is a novel approach compared to existing solutions.

Management Changes

Related Party Transactions

• There are no related party transactions with regard to Mr. Eno reportable under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders may view the appointment positively as it aligns leadership and strategy.
• The company's technology aims to improve cardiac care for patients.
• Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care.

Next Steps

• Obtain FDA clearance for the 12-lead ECG Synthesis Software.
• Initiate commercialization of the 3D ECG technology.
• Continue the Early Access Program to gather feedback and ensure operational readiness.

Key Dates

Keywords

Board of Directors, Robert Eno, CEO, HeartBeam, FDA clearance, 3D ECG, 12-lead ECG, Commercialization, Medical Technology, Cardiac Monitoring